Democratizing base editing with the Pin-point platform
To provide broad access to base editing across the research and therapeutic market, we offer Pin-point base editing reagents and services, as well as licensing to the underlying patents and patent applications.
Explore Pin-point reagents | Discover Pin-point services
A strategic asset for therapeutic developers
IP-Independent innovation
- Only base editing technology that uses RNA aptamers for deaminase recruitment
- Independent of other base editing systems, helping secure your path to commercialization
- Foundational technology established by Rutgers University and further developed by Revvity
- Only base editing technology that uses RNA aptamers for deaminase recruitment
- Independent of other base editing systems, helping secure your path to commercialization
- Foundational technology established by Rutgers University and further developed by Revvity
Engineered for clinical complexity
- Achieves precise, scarless edits while avoiding risks associated with double-strand DNA breaks
- Supports independent or simultaneous CBE and ABE editing
- Enables multiplex base editing with knock-in and knockout in a single step, ideal for T cell and iPSC-derived therapies
- Verified with AI-generated enzymes
- Achieves precise, scarless edits while avoiding risks associated with double-strand DNA breaks
- Supports independent or simultaneous CBE and ABE editing
- Enables multiplex base editing with knock-in and knockout in a single step, ideal for T cell and iPSC-derived therapies
- Verified with AI-generated enzymes
Verified, scalable, and ready-to-go
- Demonstrated clinical-grade performance in T cells, iPSCs, and HSPCs
- Low cytotoxicity and reduced off-target activity compared to other CRISPR methods
- An mRNA and synthetic sgRNA based system with a clear path to GMP
- Demonstrated clinical-grade performance in T cells, iPSCs, and HSPCs
- Low cytotoxicity and reduced off-target activity compared to other CRISPR methods
- An mRNA and synthetic sgRNA based system with a clear path to GMP
Backed by peer-reviewed science
- Molecular therapy (2024) - https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(24)00423-4
- Nature biotechnology (2025) - https://www.nature.com/articles/s41587-024-02240-0
- CRISPR journal (2020) - https://www.liebertpub.com/doi/10.1089/crispr.2020.0035
- bioRxiv (2025) - https://www.biorxiv.org/content/10.1101/2025.06.05.656583v1.full
- Molecular therapy (2024) - https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(24)00423-4
- Nature biotechnology (2025) - https://www.nature.com/articles/s41587-024-02240-0
- CRISPR journal (2020) - https://www.liebertpub.com/doi/10.1089/crispr.2020.0035
- bioRxiv (2025) - https://www.biorxiv.org/content/10.1101/2025.06.05.656583v1.full
Pin-point base editing platform capabilities at a glance
| RNA-based modularity | Interchangeable components for precise, configurable editing windows |
|---|---|
| Simultaneous KO + HDR KI | Multiplexed engineering without multiple nuclease species |
| Optimized for DSB-sensitive cells | Reduced DNA damage and improved cell viability in iPSCs, HSPCs and T cells |
| Flexible Cas & deaminase compatibility | Integrates with Type II/V nucleases and novel deaminases |
| Customizable workflows | Use Revvity reagents or partner with our expert scientists for custom service options. |
How does the Pin-point base editing platform work?
Base editing can create precise single base A to G or C to T changes in the genome through the use of an adenine or cytidine deaminase, respectively. These single base changes have the potential to correct disease causing mutations or can be used to introduce splice site disruptions or premature stop codons that can generate functional protein knockouts.
The Pin-point platform is unique because it uses an RNA aptamer on the gRNA as a "handle" to recruit the deaminase to the Cas/gRNA complex, which contains an aptamer binding sequence. Revvity’s aptamer-driven approach allows for highly complex editing, such as recruitment of an adenine deaminase to one locus and a cytidine deaminase to another locus. It also enables multiplexed knockout and knock-in (Porreca et al. Molecular Therapy 2024).
In one possible configuration of the Pin-point platform, a catalytically modified nickase Cas9 (nCas9) is directed to the target site by a single guide RNA (sgRNA) that includes an extended RNA aptamer scaffold. The RNA aptamer recruits the deaminase (here shown as a cytidine deaminase) via the aptamer binding protein domain.
Featured resources
You may also be interested in
Partner with us
Whether you’re pursuing platform diversification, clinical innovation, or IP de-risking, the Pin-point base editing platform offers a robust foundation for next-generation therapies.
Get in touch to learn more about:
- Licensing and co-development
- Technical data and protocols
- Reagent kits and custom services
Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
How can we help you?
We are here to answer your questions.